• Intranasal delivery route for neurodegenerative diseases: recent insights and future directions 

  Correale, Jorge; Mattera, Vanesa; Pasquini, Juana María (Springer, 2025-07-29)

  Neurodegenerative diseases are increasingly significant causes of mortality and morbidity worldwide, particularly among the elderly. Despite their widespread prevalence, effective treatment options remain inadequate. A ...
• Induction of immune tolerance in NMOSD and MOGAD 

  Correale, Jorge; Carnero Contentti, Edgar (Sage, 2025-08-01)

  Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are autoimmune diseases characterized by immune-mediated damage to the central nervous system. ...
• Consenso Argentino de Diagnóstico y Tratamiento de Encefalitis Autoinmune en Adultos (CARENAI) 

  Barboza, Andrés; Fernández, María Cecilia; Hryb, Javier; Latini, Manuel Facundo; Mangone, Carlos Alberto; Manin, Analisa; Marrodán, Mariano; Pereira de Silva, Nahuel; Pérez Akly, Manuel; Rojas, Galeno; Romano, Lucas; Rugilo, Carlos; Sánchez, Marina; Tourreilles, Martin; Villa, Andrés; Yorio, Florencia; Zuin, Daniel (Elsevier, 2025-07)

  Introducción La encefalitis autoinmune (EAI) es un campo en rápido crecimiento dentro de la neurología, con mayor reconocimiento gracias a los avances en la detección de anticuerpos. A pesar de su creciente incidencia, ...
• Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria 

  Montalban, Xavier; Lebrun-Frénay, Christine; Oh, Jiwon; Arrambide, Georgina; Moccia, Marcello; Amato, Maria Pia; Amezcua, Lilyana; Banwell, Brenda; Bar-Or, Amit; Barkhof, Frederik; Butzkueven, Helmut; Ciccarelli, Olga; Chataway, Jeremy; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Deisenhammer, Florian; Filippi, Massimo; Fiol, Julie; Freedman, Mark S. (Elsevier, 2025-09-17)

  Advances in the understanding of multiple sclerosis and the development of biomarkers of pathophysiology prompted a substantial revision of the 2017 McDonald diagnostic criteria. The new 2024 McDonald criteria provide a ...
• The immunological role of oligodendrocytes: beyond myelin maintenance 

  Pasquini, Juana M.; Correale, Jorge (Oxford University Press on behalf of the British Society for Immunology, 2025-04-28)

  Oligodendrocytes (OGDs) are well-established cells in the central nervous system (CNS), primarily recognized for their role in myelination. However, emerging evidence suggests intrinsic differences among OGDs that may lead ...
• Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study 

  Marrodán, Mariano; Piedrabuena, María Agustina; Zárate, María Agustina; Rodríguez Murúa, Sofía; Surace, Ezequiel Ignacio; Farez, Mauricio Franco; Fiol, Marcela Paula; Ysrraelit, María Célica; Correale, Jorge (Wiley Periodicals, 2025-08)

  Objective: Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin-4 antibodies (AQP4-IgG). Rituximab, a CD20+ B-cell depleting ...
• Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome 

  Fissolo, Nicolás; Schaedelin, Sabine; Villar, Luisa M.; Lünemann, Jan D.; Correale, Jorge; Rejdak, Konrad; Schwab, Nicholas; Vilaseca, Andreu; Held, Friederike; García-Merino, Antonio; Bittner, Stefan; Trojano, María; Furlan, Roberto; Tumani, Hayrettin; Pérez-Miralles, Francisco; Rosenstein, Igal; Galimberti, Daniela; Álvarez-Bravo, Gary; Thouvenot, Eric; Llufriu, Sara (American Medical Associatio, 2025-07-01)

  Importance: Understanding the risk factors for symptom development will allow clinicians to stratify people with radiologically isolated syndrome (pwRIS) more effectively and tailor their management strategies accordingl ...
• Development of early progression independent of relapse activity significantly impacts on disability accumulation in patients with multiple sclerosis 

  Zárate, María Agustina; Marrodán, Mariano; Piedrabuena, María Agustina; Fiol, Marcela Paula; Ysrraelit, María Célica; Correale, Jorge (Elsevier, 2025-05-14)

  Background: Disability accumulation in multiple sclerosis (MS) is driven by relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). Early PIRA (EP), occurring within five years of disease ...
• Latin American RAND/UCLA modified Delphi consensus recommendations for management and treatment of adult MOGAD patients in clinical practice 

  Carnero Contentti, Edgar; Correale, Jorge; Rojas, Juan I.; Alonso, Ricardo; Becker, Jefferson; Caparó Zamalloa, César; Correa-Díaz, Edgar Patricio; Flores-Rivera, José; Jiménez Arango, Jorge A.; Lana Peixoto, Marco A.; Navas, Carlos; Pataruco, Liliana; Rivera, Víctor M.; Sato, Douglas K.; Soto de Castillo, Ibis; Tkachuk, Verónica; Levy, Michael; Paul, Friedemann (Elsevier, 2025-04-20)

  Introduction: Over the last decade, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has seen significant advancements, with new diagnostic criteria and emerging biomarkers, increased recognition of ...
• Impact of oral Cladribine on paramagnetic rim lesions of Multiple Sclerosis patients 

  Marrodán, Mariano; Yañez, Paulina; Calandri, Ismael Luis; Piedrabuena, María Agustina; Zárate, María Agustina; Ysrraelit, María Célica; Fiol, Marcela Paula; Correale, Jorge (Elsevier, 2025-02-22)

  Background: Paramagnetic rim lesions (PRLs), marked by chronic inflammation and iron-loaded microglia, are linked to severe disease progression in multiple sclerosis (MS). The impact of cladribine, an immune reconstitution ...
• Toward equity in MS care: A roadmap for accessible treatment 

  Correale, Jorge (Sage, 2025-03-17)

  Resumen no disponible
• Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort 

  Giovannoni, Gavin; Boyko, Alexey; Correale, Jorge; Edan, Gilles; Freedman, Mark S.; Montalban, Xavier; Rammohan, Kottil; Stefoski, Dusan; Yamout, Bassem; Leist, Thomas; Aydemir, Aida; Borsi, Laszlo; di Cantogno, Elisabetta Verdun (SAGE, 2024-12-17)

  Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets. Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial. Methods: ...
• Frailty and Implications for Multiple Sclerosis Management 

  Correale, Jorge (American Medical Association, 2025-03-03)

  This Viewpoint discusses the unique needs of patients with multiple sclerosis and frailty and describes the gaps that should be addressed in frailty measurement and clinical management.
• Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder 

  Carnero Contentti, Edgar; Correale, Jorge (Taylor & Francis, 2025-02-23)

  Resumen no disponible
• Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision 

  Correale, Jorge; Marrodán, Mariano (Sage, 2024-12-18)

  Live-attenuated vaccines provide robust immunity against diseases like tuberculosis, measles, mumps, rubella, polio, yellow fever, dengue, typhoid fever, and varicella, with just one or a few doses. However, concerns arise ...
• Chapter 10 - Autoimmune Astrocytopathy 

  Correale, Jorge (Springer Nature, 2024)

  Astrocytes constitute the most abundant type of glial cells in the central nervous system (CNS) and display significant heterogeneity. Astrocytes actively engage in various metabolic processes and are active contributors ...
• Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries 

  Silva, Berenice Anabel; Ysrraelit, María Célica; Zanga, Gisela; Segamarchi, María Constanza; Cragnolini, Carolina; Galleguillos, Lorna; Halfon, Mario Javier; Miguez, Jimena; Parada Marcilla, Marcela; Pereyra, Adriana; Silva, Emanuel; Vrech, Carlos; D'Eramo, Mariana; Negrotto, Laura (Elsevier, 2025-01-14)

  The use of additional cladribine tablets treatment courses is becoming an option in patients with multiple sclerosis (MS) showing disease activity after treatment initiation. Despite the availability over the past year of ...
• Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies 

  Marrodán, Mariano; Sao Avilés, Augusto; Río, Jordi; Cobo-Calvo, Álvaro; Fernández, Victoria; Pappolla, Agustin; Castilló, Joaquín; Vidal-Jordana, Ángela; Arrambide, Georgina; Tur, Carmen; Rodríguez-Acevedo, Breogán; Zabalza, Ana; Mongay-Ochoa, Neus; Vilaseca, Andreu; Rodriguez, Marta; Galán, Ingrid; Comabella, Manuel; Sastre-Garriga, Jaume; Tintoré, Mar; Auger, Cristina (Sage, 2025-02-10)

  Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving ...
• Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies 

  Damasceno, Alfredo; Marrodán, Mariano (Future Medicine, 2025-02-12)

  What is this summary about?: Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body's natural defense system (the immune system) attacks the body's own tissues. ...
• New potential ligand-receptor axis involved in tissue repair as therapeutic targets in progressive multiple sclerosis 

  Carrera Silva, Eugenio Antonio; Correale, Jorge; Rothlin, Carla V.; Ortiz Wilczyñski, Juan Manuel (American Society for Pharmacology and Experimental Therapeutics, 2024-10-08)

  Progressive multiple sclerosis (PMS) represents the worsening phase of the disease by accumulative neurodegeneration and disability, mainly refractory to current treatments. The therapeutic options remain challenging based ...

Más